Infectious diseases are caused by various smart pathogens like bacteria, fungi, viruses, and parasites, claiming more than 17M lives globally (1). Currently, we are in the middle of a pandemic that originated from an infectious disease. The Infectious diseases are caused by various smart pathogens like bacteria, fungi, viruses, and parasites, claiming more than 17M lives globally (1). Currently, we are in the middle of a pandemic that originated from an infectious disease. The available therapies, medical facilities, and research–development teams of each country were exploited, and yet the novel coronavirus claimed ~4,065,876 lives to date. These smart pathogens keep tweaking themselves, posing challenges to treatment therapy such as antibiotic/antiviral drugs resistance, tolerance, and newer strategies to survive inside host cells. For instance, emergence and spread of the Methicillin-resistant Staphylococcus aureus (MRSA) bacterial resistance constitute a toll on human and animal health, food security, environmental sustainability, and socioeconomic development, triggering the tripartite organizations (Food and Agriculture Organization of the United Nations, FAO; World Organization for Animal Health; and World Health Organization, WHO) to layout a blueprint for tackling such resistance threats the coming five to ten years. Moreover, the novel coronavirus and drug-resistant species of influenza viruses highlighted the urgent need for new antiviral therapies (2). Most of the antibiotics and antiviral agents exhibit low stability, less solubility, extraordinary potential of drug-drug interaction, high occurrence of toxicity or adverse effects, short-half life, and low concentration at the site of infection (3). Thus, there is a desperate need for ground-breaking treatment approaches to combat these evolving infectious diseases.